FinTech
PharmAust: Continues research in neglected diseases
Clinical oncology company PharmAust (PAA) has secured an extension on its current contract with the Drugs for Neglected Diseases Initiative (DNDI)
The renewed...
FinTech
PharmAust: Awarded $881K grant for phase one monepantel trial
PharmAust (PAA) has granted $881,085 for a phase one clinical trial of monepantel in patients with Motor Neurone Disease (MND)
The Australian clinical-stage...
FinTech
PharmAust: Continues testing COVID-19 treatment
PharmAust (PAA) has revealed preliminary results show its drugs are effective in inhibiting COVID-19 in human lung cells
Researchers in Melbourne have been...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read
